AR062038A1 - Neurotrofinas modificadas post-traduccionalmente - Google Patents

Neurotrofinas modificadas post-traduccionalmente

Info

Publication number
AR062038A1
AR062038A1 ARP070103275A ARP070103275A AR062038A1 AR 062038 A1 AR062038 A1 AR 062038A1 AR P070103275 A ARP070103275 A AR P070103275A AR P070103275 A ARP070103275 A AR P070103275A AR 062038 A1 AR062038 A1 AR 062038A1
Authority
AR
Argentina
Prior art keywords
retained
conserved
trp
residue selected
post
Prior art date
Application number
ARP070103275A
Other languages
English (en)
Inventor
Pehar Mariana
Cassina Patricia
M Alzari Pedro
Barbeito Luis
Original Assignee
Pasteur Institut
Inst De Investigaciones Biolog Clemente Estable I I B C E
Facultad De Medicina Universidad De La Republica
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst De Investigaciones Biolog Clemente Estable I I B C E, Facultad De Medicina Universidad De La Republica, Centre Nat Rech Scient filed Critical Pasteur Institut
Publication of AR062038A1 publication Critical patent/AR062038A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Las neurotrofinas sufren modificaciones post-transduccionales y estas modificaciones post-transduccionales median la actividad pro-apoptótica y/o pro-neuritas de las neurotrofinas. Estas modificaciones post-transduccionales incluyen notablemente la nitración y la formación de dímeros de diferente conformación, así como también de oligómeros anormales, tales como tetrámeros y octámeros. Se proveen así agentes útiles para el tratamiento de las condiciones o enfermedades que involucran dolor crónico y/o pérdidas neuronales. Reivindicación 1: Un inductor y/o estimulador de la apoptosis neuronal motriz y/o del crecimiento de neuritas, el cual comprende: una neurotrofina modificada en una forma aislada, en donde por lo menos un residuo seleccionado de residuos Tyr y Trp comprende por lo menos un grupo nitrito, un fragmento conservado de dicha forma aislada de la neurotrofina modificada, en donde dicho fragmento conservado tiene retenido por lo menos un residuo seleccionado entre residuos Tyr y Trp, y donde dicho fragmento conservado tiene retenido por lo menos un grupo nitro en dicho al menos un residuo seleccionado entre residuos Tyr y Trp, y tiene retenida una capacidad de inducir y/o estimular la apoptosis neuronal motriz y/o el crecimiento de neuritas; o una variante conservada de dicha forma aislada de la neurotrofina modificada o de dicho fragmento conservado, en donde dicha variante conservada deriva de dicha neurotrofina modificada o de dicho fragmento conservado por la substitución y/o deleción y/o agregado de al menos un aminoácido, pero tiene retenido por lo menos un residuo seleccionado entre residuos Tyr y Trp, y donde dicha variante conservada tiene retenido por lo menos un grupo nitro en dicho al menos un residuo seleccionado entre residuos Tyr y Trp, y tiene retenida una capacidad de inducir y/o estimular la apoptosis neuronal motriz y/o el crecimiento de neuritas.
ARP070103275A 2006-07-24 2007-07-24 Neurotrofinas modificadas post-traduccionalmente AR062038A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291195A EP1882697B1 (en) 2006-07-24 2006-07-24 Antibodies, antibody fragments and scFv binding to post-translationally modified neurotrophins

Publications (1)

Publication Number Publication Date
AR062038A1 true AR062038A1 (es) 2008-08-10

Family

ID=37075006

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103275A AR062038A1 (es) 2006-07-24 2007-07-24 Neurotrofinas modificadas post-traduccionalmente

Country Status (11)

Country Link
US (2) US20100055109A1 (es)
EP (2) EP1882697B1 (es)
JP (1) JP5528803B2 (es)
AR (1) AR062038A1 (es)
AT (1) ATE465179T1 (es)
BR (1) BRPI0714545A2 (es)
CA (1) CA2657563A1 (es)
DE (1) DE602006013809D1 (es)
HK (1) HK1116806A1 (es)
UY (1) UY30501A1 (es)
WO (1) WO2008012049A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1882697B1 (en) * 2006-07-24 2010-04-21 Institut Pasteur Antibodies, antibody fragments and scFv binding to post-translationally modified neurotrophins
US20120135973A1 (en) * 2010-09-08 2012-05-31 Southern Illinois University Edwardsville Method for treating chronic pain
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
CN110869386A (zh) * 2017-02-10 2020-03-06 维维巴巴公司 重组神经生长因子的组合物和方法
AU2019243155A1 (en) * 2018-03-27 2020-10-15 Factor Bioscience Inc. Nucleic acid-based therapeutics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
US6068040A (en) 1998-07-24 2000-05-30 Alpine Overhead Doors, Inc. Slat edge retainer for overhead rolling doors
EP1500399A1 (en) 2003-07-24 2005-01-26 Institut Pasteur Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases
EP1882697B1 (en) * 2006-07-24 2010-04-21 Institut Pasteur Antibodies, antibody fragments and scFv binding to post-translationally modified neurotrophins

Also Published As

Publication number Publication date
DE602006013809D1 (de) 2010-06-02
JP5528803B2 (ja) 2014-06-25
US9328163B2 (en) 2016-05-03
WO2008012049A1 (en) 2008-01-31
EP2046823B1 (en) 2012-11-21
CA2657563A1 (en) 2008-01-31
HK1116806A1 (en) 2009-01-02
EP1882697A1 (en) 2008-01-30
EP1882697B1 (en) 2010-04-21
JP2010501475A (ja) 2010-01-21
ATE465179T1 (de) 2010-05-15
EP2046823A1 (en) 2009-04-15
BRPI0714545A2 (pt) 2013-05-14
UY30501A1 (es) 2009-04-30
US20100055109A1 (en) 2010-03-04
US20140178384A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
AR062038A1 (es) Neurotrofinas modificadas post-traduccionalmente
CO7230336A2 (es) Inhibidores de indazol de la ruta de señalización de wnt y usos terapeúticos de los mismos
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
DOP2007000051A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
EA201591281A1 (ru) Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы
NI201000033A (es) Amidas heterocíclicas útiles para el tratamiento de cáncer y psoriasis
ITMI20021527A1 (it) Anticorpi anti componente c5 del complemento e loro uso
HN2011001256A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratmiento o prevencion de diabetes
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
EA200501607A1 (ru) Замещённые фенилалкановые кислоты
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
WO2009100513A3 (pt) Peptideo des-[asp1hala1]- agonista da angiotensina-(1 -7) e composiҫões farmacêuticas para tratamento de doenças
GT200600280A (es) Composiciones y metodos para el tratamiento de sintomas relacionados con el ciclo
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CR10138A (es) 1h indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
ATE473735T1 (de) Beta-2 adrenoceptor agonisten zur behandlung von bindegewebserkrankungen der haut
UY33206A (es) Métodos de tratamiento de enfermedades autoinmunes con antagonistas de dll4
AR107579A1 (es) Composiciones y métodos para disminuir la expresión de tau
PA8601001A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
HN2012000031A (es) Terapia de combinacion para el tratamiento de la diabetes
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas
CL2008000806A1 (es) Compuestos derivados de aza piridopirimidinona, con actividad agonista de hm74a; procedimiento de preparacion de dichos compuestos; composicion farmaceutico que las comprende; y su uso para preparar medicamentos para el tratamiento de enferemedades ateroscleroticas, dislipidemias, alzheimer, diabetes, entre otras.
JO2581B1 (en) Aryl sulfonomides replaced
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)

Legal Events

Date Code Title Description
FB Suspension of granting procedure